In murine models, antibody-mediated neutralization of tumor cell-derived IL-1β has been shown to reduce MDSC accumulation, with increased tumor infiltration of CD8+ T cells, resulting in decreased tumor growth and prolonged survival, as well as enhanced responsiveness to anti-PD-1-based therapies in PDAC and renal cancer (91, 92). Here, IL1B is linked to neoplasm.